Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Statin-Intolerant Patients with Hypercholesterolemia
NCT01709513Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Started Sep 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01709513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709513.